We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information for British citizens moving to or living in Colombia, including guidance on residency, passports, healthcare and emergencies.
Information for patients who have been prescribed Paxlovid (nirmatrelvir 150mg and ritonavir 100mg) film-coated tablets COVID-19 antiviral medication.
Information about support for British nationals experiencing mental health difficulties in Turkey.
Guidance for prescribing vets on the use of the cascade.
A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
Sanofi UK is recalling the listed batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the batches of the source material of manufacturer for vigabatrin.
An investigation by the Criminal Enforcement Unit (CEU) of the Medicines and Healthcare products Regulatory Agency (MHRA) has led to charges being brought against five people from the Wolverhampton area for the illegal supply of prescription-only medicines and controlled drugs.
It's illegal to drive if you're unfit to do so because you're on legal or illegal drugs, or you have certain levels of drugs or medicine in your blood
Advice for medical professionals to follow when assessing drivers with miscellaneous conditions.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
A qualitative study
There is a risk of harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid▼ due to its inhibition of the enzyme CYP3A, which metabolises many commonly used drugs. Prescribers should obtain a detailed patient history of current...
Guidance for pharmacists on prescriptions issued in EU countries, Norway, Iceland, Liechtenstein and Switzerland.
Appendix to the assessing fitness to drive guide for medical professionals.
Actions that trial sponsors should consider to build resilience into clinical trial design
How to access the essential information you need when living in Taiwan as a British national.
Medication Adherence Clubs were set up to address the many patients requiring chronic HIV and NCD care
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.